Press Releases

30/11/2021 OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical Development of CoVepiT, its Multi-Target T-cell Anti-COVID Vaccine

17/11/2021 OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi®

16/11/2021 OSE Immunotherapeutics Presented New Translational Data on Tedopi® and Preclinical Data on PD-1/IL-7 Bifunctional Program BiCKI®-IL-7

15/11/2021 OSE Immunotherapeutics Presented the First Positive Preclinical Efficacy Data on CLEC-1

19/10/2021 OSE Immunotherapeutics to Present New Preclinical Data at Upcoming Bispecific Antibody and Immunology Conferences

13/10/2021 OSE Immunotherapeutics to Present New Clinical and Preclinical Data at the SITC

12/10/2021 OSE Immunotherapeutics to Host Today a Virtual “Immuno-Oncology R&D Day"

11/10/2021 OSE Immunotherapeutics Receives New European Patent Notice of Allowance for Tedopi®

30/09/2021 Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of BI 765063

27/09/2021 OSE Immunotherapeutics to Host an “Immuno-Oncology R&D Day” On October 12th, 2021

21/09/2021 OSE Immunotherapeutics Announces H1 2021 Results

20/09/2021 OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial

20/09/2021 OSE Immunotherapeutics To Present Positive Results of Tedopi® Phase 3 Clinical Trial

16/09/2021 Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor

13/09/2021 Boehringer Ingelheim and OSE Immunotherapeutics To Present Phase 1 Results with BI 765063

07/09/2021 OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Tedopi®

01/09/2021 OSE Immunotherapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

26/08/2021 OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi®

1 2 3 4 5 6 7 8 9 10 11 12